MAPT and neurodegenerative disease: Repurposing LAG3‐blocking antibody combination therapy has been approved by the US FDA with PD‐1 inhibition[28] and could be used for neurodegenerative diseases characterized by pathologic tau and α‐syn.[6, 7]